Assertio Holdings, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
March 11, 2024 at 04:01 pm EDT
Share
Assertio Holdings, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported revenue was USD 32.99 million compared to USD 50.35 million a year ago. Net loss was USD 57.38 million compared to net income of USD 88.55 million a year ago. Basic loss per share from continuing operations was USD 0.61 compared to basic earnings per share from continuing operations of USD 1.83 a year ago. Diluted loss per share from continuing operations was USD 0.61 compared to diluted earnings per share from continuing operations of USD 1.34 a year ago.
For the full year, revenue was USD 152.07 million compared to USD 156.23 million a year ago. Net loss was USD 331.94 million compared to net income of USD 109.63 million a year ago. Basic loss per share from continuing operations was USD 4.67 compared to basic earnings per share from continuing operations of USD 2.33 a year ago. Diluted loss per share from continuing operations was USD 4.67 compared to diluted earnings per share from continuing operations of USD 2.03 a year ago.
Assertio Holdings, Inc. is a commercial pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through acquisition or licensing of approved products. Its comprehensive commercial capabilities include marketing through both a sales force and a non-personal promotion model, market access through payor contracting and trade and distribution. The Companyâs primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, CAMBIA (diclofenac potassium for oral solution) and Zipsor (diclofenac potassium) Liquid filled capsules. INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID).
ASSERTIO HOLDINGS, INC. 
